Browse by Clinical Topic:

Featured CME/CE Content:
neuroscienceCME Editors' Picks:

Combos are Complicated! Navigating the Balance of Efficacy and Safety in Advanced Endometrial Cancer

Premiere Date: Thursday, December 2, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Creditâ„¢

Credit Expiration Date:
Friday, December 2, 2022
Note: Credit Is No Longer Available


Richard T. Penson, MD, MRCPRichard T. Penson, MD, MRCP (Moderator)
Physician at Mass General Brigham
Associate Professor
Harvard Medical School
Institutional Review Board (IRB) Chair
Dana Farber Harvard Cancer Center
Boston, MA

Nicoletta Colombo, MD, PhDNicoletta Colombo, MD, PhD 
Director, Gynecologic Oncology Program
European Institute of Oncology
Associate Professor of Obstetrics and Gynecology
University of Milan-Bicocca
Milan, Italy

Shannon N. Westin, MD, MPHShannon N. Westin, MD, MPH 
Associate Professor
Director, Early Drug Development
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas, MD Anderson Cancer Center
Houston, TX

Statement of Need

Endometrial cancer (EC) is the fourth most common malignancy in women in developed countries and the sixth most deadly malignancy in women in the United States. Women with advanced disease have fewer treatment options and a poorer prognosis. However, the treatment landscape has recently broadened to include checkpoint inhibitors and other targeted monoclonal antibodies. The exploration of various immune-targeting combinations has shed light on the prospect of synergistic antitumor effects of these agents when used together. Combination therapy approval and the clinical implications of treating patients with new agents have led to the need for education to ensure that clinicians have the knowledge and competence to translate best practices for managing treatment and adverse events (AE) into patient care.

This CMEO Live and OnDemand will provide learners with the rationale and data for new combination therapies approved for advanced EC as well as best practices to improve patient adherence to their regimens, with the goal of early recognition and appropriate management of AEs.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Examine the rationale and data leading to the approval of combination regimens in advanced EC.
  • Apply best practices to address treatment challenges related to combination therapy in advanced EC.

Financial Support

Supported by educational grants from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., and Eisai Inc.

Target Audience

Oncologists, PCPs, gynecologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Enduring material

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Penson reports the following financial relationships:

Advisory Board: AbbVie Inc.; AstraZeneca; Cancer Panels; Care4ward, Inc. (Unpaid); Eisai Inc.; Genentech, Inc.; Merck & Co.; Roche Pharmaceuticals; Sutro Biopharma, Inc.; GlaxoSmithKline; and Vascular Biogenics

Research Support: Array BioPharma Inc.; AstraZeneca; Eisai Inc.; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis U.S. LLC; Tesaro Inc.; and Vascular Biogenics

Royalties: BMJ Publishing; Elsevier Ltd.; UptoDate; Wiley Blackwell; and Wolters Kluwer Health

Dr. Colombo reports the following financial relationships:

Consultant: AstraZeneca; BIOCAD; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Mersana Therapeutics; OncXerna Therapeutics, Inc.; Pfizer Inc.; PharmaMar; Roche; and Tesaro, Inc.

Research Support: AstraZeneca and Roche

Speakers Bureau: AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; Novartis; and Tesaro, Inc.

Dr. Westin reports the following financial relationships:

Consultant: Agenus; AstraZeneca; Clovis Oncology; Eisai Inc.; EQrx, Inc.; GlaxoSmithKline; Immunogen, Inc.; Lilly; Merck & Co., Inc.; Mereo BioPharma Group; Novartis; Pfizer Inc.; Roche/Genentech, Inc.; and Zentalis Pharmaceuticals

Grants/Research Support: AstraZeneca; Bayer; Bio-Path Holdings; Clovis Oncology; Cotinga Pharmaceuticals Inc.; GlaxoSmithKline; Mereo BioPharma Group; Novartis; OncXerna Therapeutics, Inc.; Roche/Genentech, Inc.; and Zentalis Pharmaceuticals

Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.

Julie Strickland, PharmD, (planning committee) has no disclosures to report.

David Modrak, PhD, (planning committee) has no disclosures to report.

Janan Sewar, PharmD, (planning committee) has no disclosures to report.

Kathleen Blake, PhD, (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download